作者: Ross, Bryan A ; Iorio, Olivia C ; McFarland, Tom ; Lundblad, Lennart K A ; Malaeb, Dany ; Nabavi, Seyedfakhreddin ; Coutu, Felix-Antoine ; Dandurand, Ron J ; Gottfried, Stewart B

AbstractWhile conventional spirometry is associated with strenuous “forced” maximal respiratory maneuvers and infection control implications, oscillometry is not associated with these issues. However, portability, convenience of use, and interpretation remain common limitations to both techniques. This study tested the concordance and agreement between resistance measurements obtained from the handheld portable REOM device (Reo‐f, Reo‐s) with those from conventional oscillometry (R19, R5) in PFT‐confirmed “mild” (GOLD 1) and “very severe” (GOLD 4) COPD. Unadjusted and adjusted concordance (Spearman correlation) and agreement (Bland–Altman tests) served as co‐primary outcomes. Discrimination between GOLD 1 and 4 COPD (Wilcoxon rank sum test, Support Vector Machine (SVM) classifier) and patient user experience (System Utility Scale (SUS), Participant Satisfaction Survey (PSS)) served as secondary outcomes. In 17 participants (GOLD 1 n = 9, GOLD 4 n = 8), adjusted R5‐Reo‐s (0.95 [0.81, 0.98]) and R19‐Reo‐f (0.93 [0.79, 0.99]) correlations were very strong, as was agreement (mean differences: −0.07, 0.08, respectively). Statistically significant between‐group differences were observed for all four resistance parameters. Reo‐s in particular exhibited perfect discrimination between GOLD 1 and 4 disease, with some minor misclassification by Reo‐f, R5 (n = 1 each) and R19 (n = 4). User experience scores were excellent. These results support the capacity for REOM as a novel, complementary diagnostic device in COPD.

2000-11-14·Annals of Hematology3区 · 医学

Indications for the presence of an atypical protease-activated receptor on rat platelets

3区 · 医学

Article

作者: M. S. Runge ; A. Kacharava ; J. Pohl ; J. Ruef ; C. Bode

Activation of the protease-activated receptor (PAR)-1, one of four known PARs (PAR-1 to PAR-4), can be mimicked by thrombin receptor activating peptides (TRAPs) based on the PAR-1 tethered ligand. Interestingly, despite being activatable by thrombin, rodent platelets do not express PAR-1 and thus do not respond to PAR-1-derived TRAPs, indicating different activation mechanisms between human and rodent platelets. Using a rat platelet aggregation model, we determined that TRAPs based on the tethered ligand of PAR-1 fail to activate rat platelet aggregation at concentrations up to 1 mmol/l. In addition, TRAPs inhibit thrombin-mediated rat platelet aggregation, indicating the presence of a modified PAR-1 in this species. In order to determine characteristics of this putative receptor, we tested a panel of synthesized TRAPs based on the rat sequence (R) and human sequence (H) of the PAR-1 tethered ligand for their ability to inhibit thrombin-induced rat platelet aggregation. Peptides R1-9, R4-9, R4-10, and H4-10 inhibited rat platelet aggregation in response to alpha-thrombin [inhibitory concentration (IC) 50% 0.25-1.5 mmol/l]. None of these peptides blocked epinephrine-, collagen-, or arachidonic acid-induced platelet aggregation. Alanine substitution mapping of H4-10 indicated that both Leu4 and Arg5 are essential for inhibition. Inhibition of thrombin's catalytic activity required peptide concentrations tenfold higher than inhibition of platelet aggregation (IC50% 3-5 mmol/l). No prolongation of thrombin clotting time in response to TRAPs was detected at peptide concentrations up to 5 mmol/l. Our data suggest that (1) rat platelets express a PAR-1 subtype, (2) residues Leu4 and Arg5 of the tethered ligand peptide are required for binding to this new receptor, and (3) further analysis of peptide sequences might reveal a novel PAR-1 subtype.

1994-06-01·Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih

Antitumor activity of immunoconjugates composed of boanmycin and monoclonal antibody.

Article

作者: Tian, P ; Peng, Z ; Li, D ; Jiang, M ; Deng, Y ; Zhen, Y ; Xu, H ; Chen, Y

Boanmycin (bleomycin A6, BM), an antitumor antibiotic, was conjugated to monoclonal antibodies including R19, H111 and CCT2. The immunoconjugates exhibited selective cytotoxicity to related target cells including cecum cancer Hce-8693 cells, liver cancer BEL-7402 cells and leukemia CEM cells. They were highly effective against related human tumor xenografts in nude mice, and the inhibition rates by the conjugates were much higher than those by free BM. The inhibition rate by R19-BM conjugate against human cecum cancer xenografts reached 90%. BY immunoelectron microscopy, CCT2-BM conjugate showed specific binding and internalization in leukemia CEM cells. The results indicate that boanmycin-monoclonal antibody immunoconjugates are highly active both in vitro and in vivo.

100 项与 R-19 相关的药物交易

登录后查看更多信息